Status:
RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Overweight
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part...
Eligibility Criteria
Inclusion
- Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
- Have type 2 diabetes
- Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
- Have a history of at least one unsuccessful dietary effort to lose body weight
Exclusion
- Have type 1 diabetes
- Have an unstable body weight within 90 days prior to screening
- Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- Have acute or chronic hepatitis or pancreatitis
- Are taking other medications or alternative remedies to manage weight loss
Key Trial Info
Start Date :
May 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06972472
Start Date
May 19 2025
End Date
August 1 2027
Last Update
November 4 2025
Active Locations (77)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona, United States, 85375
2
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, United States, 85741
3
Norcal Endocrinology & Internal Medicine
San Ramon, California, United States, 94583
4
Southern California Clinical Research
Santa Ana, California, United States, 92701